COCA NOW Clarification COCA Memo: Monoclonal Antibodies Bamlanivimab and Etesevimab May Be Less Effective for Treating Cases of COVID-19 Caused by SARS-CoV-2 Variants 
The recent COCA NOW : Monoclonal Antibodies Bamlanivimab and Etesevimab May Be Less Effective for Treating Cases of COVID-19 Caused by SARS-CoV-2 Variants COCA notification released September 10, 2021 highlighted changes made to CDC’s Variant Classification and Definitions webpage, which primarily focused on updates to Substitutions of Therapeutic Concern. These updates contained accurate information, but unintentionally indicated a possible cause for concern that this combination monoclonal antibody product was not effective against infections with the SARS-CoV-2 Delta variant. CDC has no evidence at present that Delta variants circulating in the United States carry mutations than might confer resistance to this drug.

The information provided in the Substitutions of Concern for SARS-CoV-2 Monoclonal Antibody Therapies is based on laboratory data provided in the Fact Sheet for Health Care Providers for EUA of Bamlanivimab and Etesevimab, which indicates no change in susceptibility to bamlanivimab and etesevimab for the Delta variants. As such, clinical recommendations have not changed.

Clinicians seeking advice on the use of monoclonal antibody products authorized for emergency use in the United States for the treatment and prevention of SARS-CoV-2 should consult the NIH COVID-19 Treatment Guidelines.
The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA Products. 
For information about this update or other clinical issues, or to send your feedback, please contact us at
Clinician Outreach and Communication Activity—resources for healthcare providers
COCA RSS Feed—subscribe to be notified of conference calls, updates, and CDC guidance for health providers
Crisis & Emergency Risk Communication Training—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication
Health Alert Network—CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories

CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.

Centers for Disease Control and Prevention

1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems  |  Unsubscribe